XAIR Beyond Air, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1641631 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY41.2%
TTM net income YoY9.1%
TTM EPS YoY168.8%
Revenue 3-yr CAGR201.8%
Net income 3-yr CAGR—
Margins
Gross margin10.0%
Operating margin-321.7%
Net margin-407.3%
FCF margin-259.0%
EBITDA margin-282.6%
Returns
ROE-369.6%
ROA-99.3%
ROIC (approx.)-1,404.8%
Asset turnover0.24x
Leverage & solvency
Liabilities / assets83.1%
Debt / equity0.00x
Current ratio3.67x
Interest coverage-4.95x
Cash quality & payout
Operating cash flow / net income0.59x
Accruals ratio-40.7%
Payout ratio—
Capex / revenue18.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $7.68M | $3.71M |
| Cost of revenue | $7.43M | $5.37M |
| Gross profit | $252,000 | -$1.66M |
| R&D expense | $10.24M | $16.86M |
| SG&A expense | $19.05M | $26.02M |
| Operating income | -$29.04M | -$44.54M |
| Interest expense | $3.52M | $3.02M |
| Pretax income | -$34.33M | -$48.48M |
| Net income | -$33.25M | -$46.62M |
| EBITDA | -$25.94M | -$41.54M |
| EPS (basic) | -4.01 | -13.77 |
| EPS (diluted) | -4.01 | -13.77 |
| Weighted avg. shares (diluted) | 8.30M | 3.39M |
| Balance sheet | ||
| Cash & equivalents | $6.74M | $4.67M |
| Short-term investments | $4.90M | $2.25M |
| Receivables | $1.09M | $710,000 |
| Inventory | $1.41M | $2.42M |
| Current assets | $24.77M | $16.02M |
| PP&E, net | $8.25M | $11.01M |
| Intangibles | $1.02M | $1.22M |
| Total assets | $35.38M | $30.06M |
| Current liabilities | $6.51M | $5.00M |
| Total liabilities | $29.18M | $15.72M |
| Shareholders' equity | $6.13M | $13.58M |
| Shares outstanding | 589,639 | 4.13M |
| Cash flow statement | ||
| Operating cash flow | -$18.14M | -$38.22M |
| Capital expenditure | $1.02M | $5.88M |
| Free cash flow | -$19.17M | -$44.10M |
| Investing cash flow | -$3.67M | $14.90M |
| Financing cash flow | $29.09M | $16.65M |
| Depreciation & amortization | $3.10M | $3.00M |
| Stock-based compensation | $5.28M | $9.15M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.